SCHEMBL29408685

SCHEMBL29408685

C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)O)CC(=O)[O-])CC(=O)[O-])CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O.[111In+3]

nearest known ligand 0.81

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 10/20 0.79
SSTR2 P30874 15/20 0.76
SSTR5 P35346 11/20 0.76
SSTR3 P32745 3/20 0.75
SSTR1 P30872 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360979 0.97 SSTR4 (0.78) SSTR4SSTR2SSTR5SSTR3SSTR1
SCHEMBL29414558 0.97 SSTR4 (0.83) SSTR4SSTR2SSTR5SSTR3
SCHEMBL1651014 0.97 SSTR4 (0.83) SSTR4SSTR2SSTR5SSTR3
SCHEMBL180440 0.97 SSTR4 (0.83) SSTR4SSTR2SSTR5SSTR3
SCHEMBL29449384 0.97 SSTR4 (0.82) SSTR4SSTR2SSTR5SSTR3
SCHEMBL5069978 0.97 SSTR4 (0.82) SSTR4SSTR2SSTR5SSTR3
SCHEMBL29653935 0.92 SSTR2 (0.79) SSTR4SSTR2SSTR5SSTR3
SCHEMBL23482744 0.89 SSTR2 (0.88) SSTR4SSTR2SSTR5SSTR3SSTR1
SCHEMBL23901126 0.89 SSTR2 (0.88) SSTR4SSTR2SSTR5SSTR3SSTR1
SCHEMBL24064978 0.88 SSTR2 (0.83) SSTR4SSTR2SSTR5SSTR3SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3965751-B1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE ITM ISOTOPE TECH MUNICH SE (DE) 2022-12-28 EP claimed
US-12605447-B2 Stable formulations for radionuclide complexes ITM SOLUCIN GMBH (DE) 2026-04-21 US disclosed
US-20260069726-A1 ZWITTERIONIC COMPOUNDS AND USES THEREOF UNIV SASKATCHEWAN (CA) 2026-03-12 US disclosed
US-20250345468-A1 COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER ITM ISOTOPE TECH MUNICH SE (DE) 2025-11-13 US disclosed
EP-4615169-A2 SYNTHESIS SYTEM COMPRISING A SOLUTION TARGET FOR CYCLOTRON PRODUCTION OF RADIOMETALS AND ASSOCIATED METHOD Mayo Foundation for Medical Education and Research (US) 2025-09-10 EP disclosed
EP-3142709-B1 SYNTHESIS SYTEM COMPRISING A SOLUTION TARGET FOR CYCLOTRON PRODUCTION OF RADIOMETALS AND ASSOCIATED METHOD MAYO FOUND MEDICAL EDUCATION & RES (US) 2025-07-30 EP disclosed
US-20250170243-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2025-05-29 US disclosed
EP-4514405-A1 COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER ITM Isotope Technologies Munich SE (DE) 2025-03-05 EP disclosed
US-20240374732-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2024-11-14 US disclosed
US-20240366812-A1 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) 2024-11-07 US disclosed
EP-4065176-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotope Technologies Munich SE (DE) 2022-10-05 EP disclosed
US-20220304964-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2022-09-29 US disclosed
US-11417439-B2 Rapid isolation of cyclotron-produced gallium-68 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2022-08-16 US disclosed
WO-2022112323-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES ITM SOLUCIN GMBH (DE) 2022-06-02 WO disclosed
WO-2022111800-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES ITM SOLUCIN GMBH (DE) 2022-06-02 WO disclosed
WO-2022099420-A1 CYCLOTRON TARGET AND LANTHANUM THERANOSTIC PAIR FOR NUCLEAR MEDICINE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2022-05-19 WO disclosed
WO-2022096673-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotopen Technologien München AG (DE) 2022-05-12 WO disclosed
WO-2022096103-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotopen Technologien München AG (DE) 2022-05-12 WO disclosed
US-20220143227-A1 Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors ADVANCED ACCELERATOR APPLICATIONS (FR) 2022-05-12 US disclosed
CN-114126654-A Para-aminohippuric acid (PAH) as a kidney protective substance 同位素技术慕尼黑有限公司 2022-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250345468-A1 COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER SSTR1, SSTR3, SSTR2 SSTR4 5/4885SSTR2 3/4885SSTR5 4/4885
US-12605447-B2 Stable formulations for radionuclide complexes EPOR, CD47, PRCP SSTR4 42/4885SSTR2 15/4885SSTR5 14/4885
US-20250170243-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES SLC40A1, SLC7A11, GYPA SSTR4 1238/4885SSTR2 1096/4885SSTR5 416/4885
US-20220304964-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE PAH, SLCO1B1, SLCO2B1 SSTR4 1042/4885SSTR2 1216/4885SSTR5 695/4885
US-20240366812-A1 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer GRPR, GIPR, CCKBR SSTR4 12/4885SSTR2 15/4885SSTR5 11/4885
US-20240374732-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES SLC40A1, SLC7A11, GYPA SSTR4 1246/4885SSTR2 1080/4885SSTR5 410/4885
US-20260069726-A1 ZWITTERIONIC COMPOUNDS AND USES THEREOF CA13, SLCO2B1, SLCO2A1 SSTR4 78/4885SSTR2 80/4885SSTR5 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.